4basebio (LON:4BB) Trading Up 2.3% – Still a Buy?

4basebio PLC (LON:4BB) traded up 2.3% during trading on Wednesday . The stock traded as high as GBX 1,007.50 ($13.52) and last traded at GBX 1,007.50 ($13.52). 14 shares traded hands during trading, a decline of 99% from the average session volume of 970 shares. The stock had previously closed at GBX 985 ($13.22).

Analysts Set New Price Targets

Separately, Royal Bank Of Canada reiterated an “outperform” rating and set a GBX 1,600 ($21.47) price objective on shares of 4basebio in a research note on Thursday, March 13th.

4basebio Price Performance

The company has a current ratio of 2.73, a quick ratio of 3.52 and a debt-to-equity ratio of 201.47. The firm has a market capitalization of £129.06 million, a price-to-earnings ratio of -1,291.67 and a beta of 1.09. The company’s 50 day moving average is GBX 1,105.81 and its 200-day moving average is GBX 1,151.14.

4basebio (LON:4BB) last released its quarterly earnings data on Tuesday, May 27th. The company reported GBX (0.94) (($0.01)) earnings per share (EPS) for the quarter. Equities research analysts anticipate that 4basebio PLC will post -3.43 earnings per share for the current year.

Insider Transactions at 4basebio

In other news, insider Heikki Lanckriet purchased 2,400 shares of the company’s stock in a transaction that occurred on Wednesday, April 2nd. The stock was acquired at an average cost of GBX 1,205 ($16.17) per share, with a total value of £28,920 ($38,808.37). 68.44% of the stock is currently owned by corporate insiders.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.